Atreca Inc (FRA:0C1)
€ 0.0435 -0.0715 (-62.17%) Market Cap: 2.93 Mil Enterprise Value: -15.66 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 0/100

Atreca Inc Phase 1b ATRC-101 Clinical Data Update Call Transcript

Jul 29, 2021 / 12:00PM GMT
Release Date Price: €4.18 (-36.18%)
Operator

Ladies and gentlemen, welcome to the ATRC-101 Phase 1b initial data summary conference call. (Operator Instructions). I would now like to turn the conference over to your host, CEO, Mr. John Orwin. Sir, please go ahead.

John Orwin
Atreca, Inc. - President & CEO

Thank you very much, operator and thank you to all those joining us today. We are pleased to be hosting this conference call and webinar to present an initial data summary from the dose escalation portion of our Phase 1b trial of ATRC-101.

Joining me for the prepared remarks are Dr. Jonathan Benjamin, SVP of Clinical Research; and Dr. Tito Serafini, Chief Strategy Officer and Atreca Founder. Also on the line are Dr. [Lisha] Wang, SVP of Data Science and Informatics; Dr. Carl Millward, VP of Translational Medicine; and Herb Cross, CFO, who will be available during the Q&A session.

For those joining by phone, I'd note that we are presenting slides as part of today's program which can be viewed via the webcast. An archived replay of today's webcast and the accompanying slides

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot